COVID-19 APPEAL IMPACT REPORT

Look at what your gift achieved:

Your donation helped establish a new purpose-built high biosecurity PC3 lab to experiment on SARS-CoV-2, allowing us to evaluate drugs and vaccines. Here are just a few examples of your gift in action in the PC3 lab:

**Establishment of a COVID-19 laboratory***:

- $10,000: New decontamination equipment
- $40,000: Two freezers set to -80C
- $20,000: Two microscopes with camera and monitor
- $800: Containment chamber for transporting SARS-CoV-2 cultures

**Maintenance of the facility over one year***:

- $10,000: Air pressure containment testing
- $25,000: Personal Protective Equipment (gloves, masks, gowns) and disposals
- $30,000: Annual decontamination of COVID-19 suites
- $70,000: Building Management System (BMS) maintenance and developments

*The above figures provide an example of a selection of approximate costs of establishing a COVID-19 laboratory and procuring specialist technologies, and typical costs of maintaining the facility over one year.
Attacking the virus from all sides

In just a few months, your generosity has made it possible for our scientists to spring into action, using the Institute’s expertise in infectious diseases to develop wide-ranging research to better understand the virus, stop people getting infected and find effective treatments for people stricken by the disease. Here are some updates from our scientists at the frontline of COVID-19 research and trials. None of this would have happened without the generosity of people like you.

Immunity in COVID-19

Associate Professor Corey Smith, Translational & Human Immunology Lab

Blood cancer treatments target immune cells that make antibodies to fight viruses. As COVID-19 is a new virus, it will allow us to understand how cancer treatment affects viral immunity. The research team is examining how those who have recovered from COVID-19 responded to the virus with the end goal of developing a new T cell immunotherapy.

Discovery of drugs for treating cardiac dysfunction

Associate Professor James Hudson, Cardiac Bioengineering Lab

SARS-CoV-2 leads to cardiac injury and dysfunction in two-thirds of hospitalised patients and higher rates of mortality in people with pre-existing cardiovascular disease. Associate Professor Hudson and his team have conducted studies into the effects of COVID-19 on the heart and will soon be publishing results.

First-in-class drugs to prevent severe stage COVID-19

Professor Sudha Rao, Gene Regulation & Translational Medicine Lab

Asymptomatic patients who display no viral symptoms are capable of being highly contagious and represent a significant danger of spreading of the virus. There is an urgent need for new post-exposure prophylaxis drugs. Professor Rao is seeking further funding to undertake these critical studies to advance her new class of drugs to the clinic for the treatment of patients diagnosed with early stage COVID-19.

Queensland-specific modelling of the pandemic

Dr James Roberts, Brain Modelling Lab

Australia is likely to be at risk of new waves of COVID-19 infection in the future. The Brain Modelling Lab is using mathematical modelling to explore outbreak scenarios and preventative intervention strategies in Queensland.

For the full list of QIMR Berghofer COVID-19 research and trials, visit our website: www.qimrberghofer.edu.au/COVID-19
YOU GAVE US

- $1.9 million for priority COVID-19 research from Australian individuals, with support across the country.
- 1,337 gifts received from 1,296 donors – some people gave twice!

- 317 people gave to the Institute for the first time.
- 80 donors came back to us...for one individual donor, his last gift was 18 years ago – thank you and welcome back to our community!

With your continued support, QIMR Berghofer will continue to play an essential role on the world stage with our ground-breaking research and collaborations.

Total number of infections worldwide

59,628,581

Deaths globally

1,406,449

COVID-19 Worldwide Statistics

Daily cases